EMA's safety-labelling list lands in a busy week for PRAC reviews and PSUSA outcomes

What happened

On 30 October 2026 the European Medicines Agency published a list of centrally authorised medicines whose product information has been changed for safety reasons. The record available to us gives the publication date and the document type, a spreadsheet. It does not say which products are on the list, what the changes are, or how many entries there are. Anything beyond that has to come from the document itself.

The list did not appear in isolation. The same day, EMA and AIFA reported that the Pharmacovigilance Risk Assessment Committee (PRAC) had opened new reviews, and EMA posted four periodic safety update report single assessment (PSUSA) outcomes. Germany's PEI and BfArM, meanwhile, backed the international #MedSafetyWeek campaign. Together these items show the EU safety system working at several points of the lifecycle at once.

Why a labelling-change list matters

Safety-related product information changes are where pharmacovigilance work becomes visible to prescribers and patients. A signal, a PSUSA or a referral eventually has to be turned into revised wording in the summary of product characteristics and package leaflet. A consolidated list helps PV teams check, product by product, whether EMA's view of the safety wording matches their own.

For marketing authorisation holders (MAHs) of centrally authorised products, the practical use is a reconciliation exercise. Does your product appear? Is the wording in your core safety information, risk management plan and local labels aligned with what was published? Teams holding products outside the central procedure can still read the list as a guide to what class-level or similar-product wording the Agency considers necessary. That reading should be careful, since the record does not describe the underlying rationale for any entry.

Regulatory context: new PRAC reviews

The PRAC items add forward-looking context. According to EMA, the committee opened a referral on flupentixol/melitracen, the combination marketed as Deanxit. AIFA describes the concern as serious neurological and psychiatric effects. PRAC also opened a review of hypersensitivity clusters across all human normal immunoglobulin medicines. AIFA ties this to reports linked to immunoglobulin batches.

The two sources give different meeting dates: EMA's highlights page refers to 26–29 October 2026, while AIFA's title says 28–30 October. We do not know the reason for the difference, so check the official meeting documents before citing a date.

Neither review has an outcome yet. Referrals and reviews of this kind can lead to changes in product information or other risk-minimisation measures, but the records give no indication of what PRAC will conclude or when. The immunoglobulin review is notable because it spans a whole product class and focuses on batch-linked reports, which puts batch traceability and complaint handling in play for MAHs.

Routine outcomes: four 'maintenance' PSUSAs

EMA also published PSUSA outcomes for gliclazide, tenoxicam, nitrofurantoin (including nitrofurantoin/pyridoxine hydrochloride) and cystine/pyridoxine hydrochloride. All four have a regulatory outcome of 'maintenance', meaning the marketing authorisations are to be maintained. In general terms, a PSUSA is a single EU-wide assessment of periodic safety update reports for the same active substance or combination, covering products authorised nationally and centrally. A maintenance outcome means the assessment did not lead to a change in the terms of the authorisations. The records do not mention any product information wording changes for these four.

The contrast is useful. Within one day the EU system produced a list of safety-driven labelling changes, several outcomes with no change to the authorisations, and two new reviews with open questions. Not every safety evaluation ends in a label update. PV teams should still read each PSUSA document and its list of nationally authorised products to confirm their products are covered.

Who is affected and what to watch

QPPVs and PV leads for centrally authorised products are the primary audience for the list. Holders of national authorisations for the four PSUSA substances should check their product coverage. Immunoglobulin MAHs and holders of flupentixol/melitracen products should prepare for questions from PRAC and national authorities, though no specific requests are described in the records.

Reporting culture is a further thread. PEI and BfArM have joined the 2–8 November #MedSafetyWeek campaign, urging professionals and patients to report suspected side effects so risks are spotted earlier. Case volumes and quality feed the signal detection that drives the work described above.

A US item is a reminder that diagnostics are part of the safety picture. FDA flagged its most serious recall category for four lots of Werfen's HemosIL AcuStar HIT-IgG(PF4-H), a heparin-induced thrombocytopenia antibody assay. The agency says the lots show negative bias that routine calibration and quality control may miss, and a supply interruption is expected. Drug-safety teams handling heparin cases could see delays or inconsistencies in how such cases are worked up. The records do not describe any link to specific drug safety conclusions.